Open an account

Milestone Pharmaceuticals

MIST · NASDAQ

$0.6482−$0.0545 (−7.76%)TodayMarket closed ·
Prev close $0.7027

About MIST

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 38 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.

Employees
38
Headquarters
MONTREAL, Quebec
Listed
May 9, 2019
Sector
Health Care
Industry
Pharmaceuticals
Website
milestonepharma.com

MIST key statistics

Market cap
80.70M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.04M
Volume
1.58M
Open price
$0.71
High today
$0.71
Low today
$0.6337
52 Week high
$3.06
52 Week low
$0.69

Milestone Pharmaceuticals (MIST) at a glance

Milestone Pharmaceuticals (MIST) last traded at $0.6482, with a market cap of 80.70M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.6337 and $0.71. The current price is 2.3% above the day's low and 8.7% below its high.

Volume so far is 1.58M shares, above the average of 1.04M shares a day.

Over the past year Milestone Pharmaceuticals has ranged from $0.69 to $3.06, and now sits -2% of the way up that range.

Milestone Pharmaceuticals met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.21 per share against an estimate of -$0.1989.

The average analyst price target is $5.97, 821.7% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 9 analystsAvg $5.97
Low
$2.02
Now
$0.6482
High
$8.40

MIST earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 22.1% on average.

  1. Q3 FY24: reported -$0.14 per share against an estimate of -$0.1666
  2. Q4 FY24: reported -$0.199 per share against an estimate of -$0.1556
  3. Q1 FY25: reported -$0.31 per share against an estimate of -$0.1887
  4. Q2 FY25: reported -$0.20 per share against an estimate of -$0.1811
  5. Q3 FY25: reported -$0.12 per share against an estimate of -$0.1673
  6. Q4 FY25: reported -$0.18 per share against an estimate of -$0.1632
  7. Q1 FY26: reported -$0.20 per share against an estimate of $0.3128
  8. Q2 FY26: reported -$0.21 per share against an estimate of -$0.1989

MIST news

  • Press releaseGlobe Newswire

    Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

  • Press releaseGlobe Newswire

    Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

  • Press releaseBusiness Wire

    Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board

  • Press releaseGlobe Newswire

    Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

  • Dylan Berman

    Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Milestone Expands CARDAMYST Push Into Europe, China And New AFib Trial

  • Press releaseGlobe Newswire

    Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.